Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection - Winkler, Emma S.; Gilchuk, Pavlo; Yu, Jinsheng; Bailey, Adam L.; Chen, Rita E.; Chong, Zhenlu; Zost, Seth J.; Jang, Hyesun; Huang, Ying; Allen, James D.; Case, James Brett; Sutton, Rachel E.; et al. (Cell, 2021)
Keywords: Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; Antibodies, Neutralizing - immunology; Antibodies, Neutralizing - therapeutic use; Antibodies, Viral - immunology; Antibodies, Viral - therapeutic use; antibody; CD8+ T cells; CD8-Positive T-Lymphocytes - cytology; CD8-Positive T-Lymphocytes - immunology; Chlorocebus aethiops; CHO Cells; COVID-19 - immunology; COVID-19 - therapy; COVID-19 infection; Cricetulus; Disease Models, Animal; disease prevention; effector function; Female; Humans; Immunoglobulin Fc Fragments - immunology; inflammation; loss-of-function mutation; lung; lungs; Male; mechanics; mechanism of action; Mice; Mice, Inbred C57BL; monocytes; mouse model; pathogenesis; respiratory tract diseases; RNA sequencing; SARS-CoV-2; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; therapeutics; therapy; tissue repair; transcription (genetics); Vero Cells; Viral Load; RNA sequencing; lung; effector function; monocytes; pathogenesis; SARS-CoV-2; CD8+ T cells; antibody; mouse model; therapy